Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.66 |
| ▸ | CTSS | P25774 | 2/20 | 0.66 |
| ▸ | CTSK | P43235 | 2/20 | 0.66 |
| ▸ | CTSB | P07858 | 1/20 | 0.66 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LAP3 | P28838 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17559 | 1.00 | CTSL (0.66) | CTSLCTSSCTSKCTSBCAPN1 | |
| SCHEMBL17560 | 1.00 | CTSL (0.66) | CTSLCTSSCTSKCTSBCAPN1 | |
| Fluoride SCHEMBL27561259 | 0.98 | CTSL (0.64) | CTSLCTSSCTSKCTSBCAPN1 | |
| Water SCHEMBL11331808 | 0.98 | CTSS (0.68) | CTSLCTSSCTSKCTSBCAPN1 | |
| Water SCHEMBL1069558 | 0.98 | CTSS (0.68) | CTSLCTSSCTSKCTSBCAPN1 | |
| Water SCHEMBL645995 | 0.98 | CTSS (0.68) | CTSLCTSSCTSKCTSBCAPN1 | |
| SCHEMBL28058660 | 0.98 | CTSL (0.64) | CTSLCTSSCTSKCTSBCAPN1 | |
| SCHEMBL8579795 | 0.98 | CTSL (0.64) | CTSLCTSSCTSKCTSBCAPN1 | |
| Water SCHEMBL2838131 | 0.98 | CTSS (0.68) | CTSLCTSSCTSKCTSBCAPN1 | |
| Hydrazine SCHEMBL8410651 | 0.97 | CTSL (0.62) | CTSLCTSSCTSKCTSBCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 366 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120192379-A | Marine cyclic peptide and synthesis method and application thereof | 内蒙古大学 | 2025-06-24 | — | — | CN | claimed |
| CN-120136948-A | Cycloastragal derivative with activity of resisting methicillin-resistant staphylococcus aureus and preparation method thereof | 山西医科大学 | 2025-06-13 | — | — | CN | claimed |
| US-20250100999-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2025-03-27 | — | — | US | claimed |
| WO-2025019172-A1 | ANTIMICROBIAL EXTRACTANT FORMED FROM COPPER-CONTAINING SOURCE | CORNING INCORPORATED (US) | 2025-01-23 | — | — | WO | claimed |
| WO-2024017221-A1 | SYNTHESIS METHOD FOR α-AZIDO KETONE CONTAINING TERTIARY STEREOCENTER | 常州大学 | 2024-01-25 | — | — | WO | claimed |
| EP-4253366-A2 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | Gilead Sciences, Inc. (US) | 2023-10-04 | — | — | EP | claimed |
| US-11760746-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2023-09-19 | — | — | US | claimed |
| CN-115108937-B | Synthesis method of alpha-azido ketone containing three-level stereo center | 常州大学 | 2023-08-22 | — | — | CN | claimed |
| CN-112055712-B | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections | 吉利德科学公司 | 2023-07-14 | — | — | CN | claimed |
| EP-3752496-B1 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | GILEAD SCIENCES INC (US) | 2023-07-05 | — | — | EP | claimed |
| CN-116023347-A | Method for preparing carfilzomib side chain isomer | 无锡紫杉药业股份有限公司 | 2023-04-28 | — | — | CN | claimed |
| CN-115368352-A | Glucokinase agonist and preparation method and application thereof | 南京盛德瑞尔医药科技有限公司 | 2022-11-22 | — | — | CN | claimed |
| CN-115108937-A | Synthesis method of alpha-azidoketone containing three-level stereocenter | 常州大学 | 2022-09-27 | — | — | CN | claimed |
| CN-109438363-B | Liquid-phase high-purity large-scale synthesis method of cyclic (leucyl-arginyl) dipeptide salt | 陕西慧康生物科技有限责任公司 | 2022-04-29 | — | — | CN | claimed |
| EP-3988538-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | claimed |
| CN-114195741-A | Preparation method of carfilzomib key intermediate isomer | 南京格亚医药科技有限公司 | 2022-03-18 | — | — | CN | claimed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| CN-112110834-A | Modified hydrophobic auxiliary material and preparation method and application thereof | 浙江智达药业有限公司 | 2020-12-22 | — | — | CN | claimed |
| CN-116854630-B | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections | 吉利德科学公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| US-12472165-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-18 | — | — | US | disclosed |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | ZHOU YUHANG (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4613745-A2 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | Gilead Sciences, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250268979-A1 | COMBINATION OF MACROCYCLIC CFTR MODULATORS WITH CFTR CORRECTORS AND / OR CFTR POTENTIATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-08-28 | — | — | US | disclosed |
| US-20250269043-A1 | TARGETED BIFUNCTIONAL DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-08-28 | — | — | US | disclosed |
| US-20250243196-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION | 2025-07-31 | — | — | US | disclosed |
| US-12365666-B2 | Process for preparing a Cot inhibitor compound | GILEAD SCIENCES, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| CN-120192379-A | Marine cyclic peptide and synthesis method and application thereof | 内蒙古大学 | 2025-06-24 | — | — | CN | disclosed |
| CN-120136948-A | Cycloastragal derivative with activity of resisting methicillin-resistant staphylococcus aureus and preparation method thereof | 山西医科大学 | 2025-06-13 | — | — | CN | disclosed |
| US-20250179118-A1 | NOVEL DIPEPTIDE COMPOUNDS AND USES THEREOF | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES, LTD. (CN) | 2025-06-05 | — | — | US | disclosed |
| CN-120058576-A | Pleuromutilin derivative with amino acid fragment, and preparation method and application thereof | 中国医学科学院药物研究所 | 2025-05-30 | — | — | CN | disclosed |
| EP-4126862-B1 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-12295942-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-05-13 | — | — | US | disclosed |
| US-20250100999-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2025-03-27 | — | — | US | disclosed |
| CN-116874515-B | Amino acid-BSH targeted hybrid compound, and preparation method and application thereof | 重庆高硼生物科技有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119613312-A | With C2Chiral primary amine catalyst with axisymmetric structure, and preparation method and application thereof | 石河子大学 | 2025-03-14 | — | — | CN | disclosed |
| CN-114163437-B | Substituted pyrazolo [1,5-a ] pyridine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2025-03-04 | — | — | CN | disclosed |
| EP-3873916-B1 | NOVEL DIPEPTIDE COMPOUNDS AND USES THEREOF | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO LTD (CN) | 2025-02-19 | — | — | EP | disclosed |
| CN-119390681-A | Process for preparing COT inhibitor compounds | 吉利德科学公司 | 2025-02-07 | — | — | CN | disclosed |
| US-12215100-B2 | Anticancer compounds | PHARMA MAR, S.A. (ES) | 2025-02-04 | — | — | US | disclosed |
| US-12213965-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-02-04 | — | — | US | disclosed |
| US-12209141-B2 | Dipeptide compounds and uses thereof | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES, LTD. (CN) | 2025-01-28 | — | — | US | disclosed |
| WO-2025019172-A1 | ANTIMICROBIAL EXTRACTANT FORMED FROM COPPER-CONTAINING SOURCE | CORNING INCORPORATED (US) | 2025-01-23 | — | — | WO | disclosed |
| EP-4493221-A2 | TARGETED BIFUNCTIONAL DEGRADERS | Yale University (US) | 2025-01-22 | — | — | EP | disclosed |
| CN-119212727-A | Targeted bifunctional degradants | 耶鲁大学 | 2024-12-27 | — | — | CN | disclosed |
| CN-113195515-B | Novel dipeptide compounds and use thereof | 丽珠医药集团股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| US-12122765-B2 | Methods and intermediates for preparing therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| CN-115397824-B | Process for preparing COT inhibitor compounds | 吉利德科学公司 | 2024-10-22 | — | — | CN | disclosed |
| EP-3988538-B1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO LTD (CN) | 2024-08-07 | — | — | EP | disclosed |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-27 | — | — | US | disclosed |
| US-20240199579-A1 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | GILEAD SCIENCES, INC. | 2024-06-20 | — | — | US | disclosed |
| US-12005046-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-12005047-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2024-06-11 | — | — | US | disclosed |
| US-11981660-B2 | Neurite outgrowth promoters and uses thereof | UNIVERSITY OF MIAMI (US) | 2024-05-14 | — | — | US | disclosed |
| CN-116813691-B | Novel dipeptide compounds and use thereof | 丽珠医药集团股份有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20240101533-A1 | METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2024-03-28 | — | — | US | disclosed |
| CN-116041361-B | Amino acid derivative of parthenolide, and preparation method and application thereof | 山东第一医科大学(山东省医学科学院) | 2024-03-26 | — | — | CN | disclosed |
| US-20240091205-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2024-03-21 | — | — | US | disclosed |
| US-11932628-B2 | Selective small molecule peptidomimetic melanocortin ligands | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2024-03-19 | — | — | US | disclosed |
| US-11911369-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-02-27 | — | — | US | disclosed |
| WO-2024032852-A1 | CYCLOACETAMIDE, NOVEL NATURAL PRODUCT FROM MORTIERELLA ALPINA, PROCESS FOR PRODUCTION THEREOF, USE THEREOF AND MORTIERELLA ALPINA DSM 34346 | FRIEDRICH-SCHILLER-UNIVERSITÄT JENA (DE) | 2024-02-15 | — | — | WO | disclosed |
| CN-116496288-B | Amine derivative protected by parthenolide Boc and preparation method and application thereof | 山东第一医科大学(山东省医学科学院) | 2024-01-26 | — | — | CN | disclosed |
| WO-2024017221-A1 | SYNTHESIS METHOD FOR α-AZIDO KETONE CONTAINING TERTIARY STEREOCENTER | 常州大学 | 2024-01-25 | — | — | WO | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| US-11845737-B2 | Process for preparing a Cot inhibitor compound | GILEAD SCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| EP-3612532-B1 | VMAT2 INHIBITOR COMPOUNDS AND COMPOSITIONS THEREOF | NEUROCRINE BIOSCIENCES INC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230381150-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-11-30 | — | — | US | disclosed |
| US-20230381149-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-11-30 | — | — | US | disclosed |
| US-20230365587-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-11-16 | — | — | US | disclosed |
| US-20230365587-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-11-16 | — | — | US | disclosed |
| CN-109641863-B | Intermediate for synthesizing carfilzomib and synthesis of pharmaceutically acceptable salt thereof | 美国安进公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116874515-A | Amino acid-BSH targeted hybrid compound, and preparation method and application thereof | 重庆高硼生物科技有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-116854630-A | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections | 吉利德科学公司 | 2023-10-10 | — | — | CN | disclosed |
| EP-4253366-A2 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | Gilead Sciences, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-116813691-A | Novel dipeptide compounds and use thereof | 丽珠医药集团股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023178199-A2 | TARGETED BIFUNCTIONAL DEGRADERS | YALE UNIVERSITY (US) | 2023-09-21 | — | — | WO | disclosed |
| CN-116670143-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-115108937-B | Synthesis method of alpha-azido ketone containing three-level stereo center | 常州大学 | 2023-08-22 | — | — | CN | disclosed |
| EP-4225447-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-115368352-B | Glucokinase agonist and preparation method and application thereof | 南京盛德瑞尔医药科技有限公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-3898613-B1 | ANTICANCER COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-09 | — | — | EP | disclosed |
| CN-116496288-A | Amine derivative protected by parthenolide Boc and preparation method and application thereof | 山东第一医科大学(山东省医学科学院) | 2023-07-28 | — | — | CN | disclosed |
| US-11708341-B2 | Synthesis of (S)-2-amino-4-methyl-((R)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof | AMGEN INC. | 2023-07-25 | — | — | US | disclosed |
| US-11708341-B2 | Synthesis of (S)-2-amino-4-methyl-((R)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof | AMGEN INC. | 2023-07-25 | — | — | US | disclosed |
| CN-112055712-B | Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviral infections | 吉利德科学公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-3752496-B1 | METHODS AND INTERMEDIATES FOR PREPARING A THERAPEUTIC COMPOUND USEFUL IN THE TREATMENT OF RETROVIRIDAE VIRAL INFECTION | GILEAD SCIENCES INC (US) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023078410-A1 | COMPOUND HAVING ACTIVITY OF DEGRADING GSPT1 AND APPLICATION THEREOF | 上海美志医药科技有限公司 | 2023-05-11 | — | — | WO | disclosed |
| CN-116041361-A | Amino acid derivative of parthenolide, and preparation method and application thereof | 山东第一医科大学(山东省医学科学院) | 2023-05-02 | — | — | CN | disclosed |
| CN-116023347-A | Method for preparing carfilzomib side chain isomer | 无锡紫杉药业股份有限公司 | 2023-04-28 | — | — | CN | disclosed |
| CN-116023347-A | Method for preparing carfilzomib side chain isomer | 无锡紫杉药业股份有限公司 | 2023-04-28 | — | — | CN | disclosed |
| CN-115925615-A | Preparation method of optically pure 2-methylpiperidine-5-amine | 甘肃皓天医药科技有限责任公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-110770236-B | VMAT2 inhibitor compounds and compositions thereof | 纽罗克里生物科学有限公司 | 2023-03-24 | — | — | CN | disclosed |
| US-20230087994-A1 | TARGETED BIFUNCTIONAL DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-23 | — | — | US | disclosed |
| EP-3727378-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME LLC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11583538-B2 | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors | Venenum Biodesign, LLC (US) | 2023-02-21 | — | — | US | disclosed |
| EP-4126862-A1 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | GILEAD SCIENCES, INC. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20230017637-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2023-01-19 | — | — | US | disclosed |
| US-20220396555-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD. (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220388947-A1 | Nitrogen-containing Derivative of Substituted Phenol Hydroxy Acid Ester, and Preparation and Use Thereof | WEST CHINA HOSPITAL, SICHUAN UNIVERSITY (CN) | 2022-12-08 | — | — | US | disclosed |
| US-20220380340-A1 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | GILEAD SCIENCES, INC. | 2022-12-01 | — | — | US | disclosed |
| CN-115368352-A | Glucokinase agonist and preparation method and application thereof | 南京盛德瑞尔医药科技有限公司 | 2022-11-22 | — | — | CN | disclosed |
| CN-115315272-A | Targeting difunctional degradation agent | 耶鲁大学 | 2022-11-08 | — | — | CN | disclosed |
| CN-112110834-B | Modified hydrophobic auxiliary material and preparation method and application thereof | 浙江智达药业有限公司 | 2022-10-21 | — | — | CN | disclosed |
| WO-2022216717-A1 | CITRON KINASE INHIBITORS | THE CLEVELAND CLINIC FOUNDATION (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20220326230-A1 | NOVEL FLAVORS, FLAVOR MODIFIERS, TASTANTS, TASTE ENHANCERS, UMAMI OR SWEET TASTANTS, AND/OR ENHANCERS AND USE THEREOF | FIRMENICH INCORPORATED (US) | 2022-10-13 | — | — | US | disclosed |
| CN-115108937-A | Synthesis method of alpha-azidoketone containing three-level stereocenter | 常州大学 | 2022-09-27 | — | — | CN | disclosed |
| EP-4041262-A1 | TARGETED BIFUNCTIONAL DEGRADERS | Yale University (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20220213068-A1 | SELECTIVE SMALL MOLECULE PEPTIDOMIMETIC MELANOCORTIN LIGANDS | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES | 2022-07-07 | — | — | US | disclosed |
| US-20220213111-A1 | SUBSTITUTED HETEROCYCLES AS CYCLIC TREX1 INHIBITORS | Venenum Biodesign, LLC (US) | 2022-07-07 | — | — | US | disclosed |
| EP-4011870-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING RILUZOLE PRODRUGS | Biohaven Pharmaceutical Holding Company Ltd. (US) | 2022-06-15 | — | — | EP | disclosed |
| US-20220177471-A1 | N-1 BRANCHED ALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2022-06-09 | — | — | US | disclosed |
| CN-109438363-B | Liquid-phase high-purity large-scale synthesis method of cyclic (leucyl-arginyl) dipeptide salt | 陕西慧康生物科技有限责任公司 | 2022-04-29 | — | — | CN | disclosed |
| EP-3988538-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | disclosed |
| CN-110267960-B | Substituted pyrazolo [1,5-a ] pyrazine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2022-04-26 | — | — | CN | disclosed |
| US-11306098-B2 | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors | Venenum Biodesign, LLC (US) | 2022-04-19 | — | — | US | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022075974-A1 | CYCLIC TREX1 INHIBITORS | Venenum Biodesign, LLC (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220110909-A1 | PREPARATION METHOD AND USE OF MODIFIED HYDROPHOBIC EXCIPIENT | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | disclosed |
| US-20220111056-A1 | DRUG-LOADED EMULSION | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | disclosed |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | disclosed |
| EP-3980415-A1 | N-1 BRANCHED ALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | 3M Innovative Properties Company (US) | 2022-04-13 | — | — | EP | disclosed |
| WO-2022073003-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | NEW YORK BLOOD CENTER, INC (US) | 2022-04-07 | — | — | WO | disclosed |
| CN-114195741-A | Preparation method of carfilzomib key intermediate isomer | 南京格亚医药科技有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-114195741-A | Preparation method of carfilzomib key intermediate isomer | 南京格亚医药科技有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-11268952-B2 | Flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof | FIRMENICH INCORPORATED (US) | 2022-03-08 | — | — | US | disclosed |
| US-20220056021-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2022-02-24 | — | — | US | disclosed |
| EP-3953333-A1 | NOVEL CYCLIC TREX1 INHIBITORS | Venenum Biodesign, LLC (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20210395299-A1 | NOVEL DIPEPTIDE COMPOUNDS AND USES THEREOF | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES, LTD. (CN) | 2021-12-23 | — | — | US | disclosed |
| US-11179389-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME CORP. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11179389-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME CORP. (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3873916-A1 | NOVEL DIPEPTIDE COMPOUNDS AND USES THEREOF | Huahai US Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| US-20210236470-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | 2021-08-05 | — | — | US | disclosed |
| US-20210236471-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2021-08-05 | — | — | US | disclosed |
| CN-113195515-A | Novel dipeptides and uses thereof | 华海美国公司 | 2021-07-30 | — | — | CN | disclosed |
| US-20210228549-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2021-07-29 | — | — | US | disclosed |
| EP-3297678-B1 | AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS LTD (IN) | 2021-07-07 | — | — | EP | disclosed |
| US-11052070-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-07-06 | — | — | US | disclosed |
| CN-107567438-B | Riluzole prodrugs and uses thereof | 拜尔哈文制药股份有限公司 | 2021-06-29 | — | — | CN | disclosed |
| US-11040970-B2 | VMAT2 inhibitor compounds and compositions thereof | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| WO-2021078073-A1 | N-CONTAINING DERIVATIVE OF SUBSTITUTED PHENOL HYDROXY ACID ESTER, AND PREPARATION AND USE THEREOF | 四川大学华西医院 | 2021-04-29 | — | — | WO | disclosed |
| CN-109553633-B | Preparation method of phenylacetic acid type aryne | 湖北大学 | 2021-03-19 | — | — | CN | disclosed |
| US-10905681-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-02-02 | — | — | US | disclosed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | disclosed |
| CN-112110834-A | Modified hydrophobic auxiliary material and preparation method and application thereof | 浙江智达药业有限公司 | 2020-12-22 | — | — | CN | disclosed |
| US-20200390760-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200390760-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2020-12-17 | — | — | US | disclosed |
| WO-2020245706-A1 | N-1 BRANCHED ALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-12-10 | — | — | WO | disclosed |
| EP-3494108-B1 | SYNTHESIS OF (S)-2-AMINO-4-METHYL-1-((R)-2-METHYLOXIRANE-2-YL)-PENTAN-1-ONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | AMGEN INC (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10800809-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | LAURUS LABS LIMITED (IN) | 2020-10-13 | — | — | US | disclosed |
| US-20200289475-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2020-09-17 | — | — | US | disclosed |
| EP-3478662-B1 | AZADECALIN DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO5) LTD (GB) | 2020-09-16 | — | — | EP | disclosed |
| US-10639298-B2 | Prodrugs of riluzole and their method of use | BIOHAVEN THERAPEUTICS LTD. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20200131173-A1 | VMAT2 INHIBITOR COMPOUNDS AND COMPOSITIONS THEREOF | NEUROCRINE BIOSCIENCES, INC. | 2020-04-30 | — | — | US | disclosed |
| US-20200085794-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD. (JP) | 2020-03-19 | — | — | US | disclosed |
| EP-3612532-A1 | VMAT2 INHIBITOR COMPOUNDS AND COMPOSITIONS THEREOF | Neurocrine Biosciences, Inc. (US) | 2020-02-26 | — | — | EP | disclosed |
| CN-110770236-A | VMAT2 inhibitor compounds and compositions thereof | 纽罗克里生物科学有限公司 | 2020-02-07 | — | — | CN | disclosed |
| US-20190292149-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA LP (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190284231-A1 | PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS LIMITED (IN) | 2019-09-19 | — | — | US | disclosed |
| US-10364269-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | LAURUS LABS LIMITED (IN) | 2019-07-30 | — | — | US | disclosed |
| EP-3466961-A1 | PROLINAMIDE DERIVATIVE AS THROMBIN INHIBITOR, PREPARATION METHOD AND APPLICATION THEREOF | Li, Min (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10253027-B2 | Aryl lactam kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-09 | — | — | US | disclosed |
| US-10242871-B2 | Resist underlayer film-forming composition including a compound having an amino group protected with a tert-butoxycarbonyl group | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2019-03-26 | — | — | US | disclosed |
| US-20190085026-A1 | AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Laurus Labs Ltd. (IN) | 2019-03-21 | — | — | US | disclosed |
| US-10208023-B2 | Heterocyclic inhibitors of the sodium channel | DeGiacomo, Mark G. (US) | 2019-02-19 | — | — | US | disclosed |
| WO-2018195121-A1 | VMAT2 INHIBITOR COMPOUNDS AND COMPOSITIONS THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2018-10-25 | — | — | WO | disclosed |
| US-10035777-B2 | Heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-31 | — | — | US | disclosed |
| CN-105517993-B | Aryl amide kinase inhibitors | 百时美施贵宝公司 | 2018-07-13 | — | — | CN | disclosed |
| EP-3054955-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-2822559-B1 | IMIDAZO[1,2-B]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF | LEXICON PHARMACEUTICALS INC (US) | 2018-05-02 | — | — | EP | disclosed |
| CN-107935988-A | Optionally substituted quinoline compounds | 卫材R&D管理有限公司 | 2018-04-20 | — | — | CN | disclosed |
| EP-3057948-B1 | SELECTIVELY SUBSTITUTED QUINOLINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2018-03-14 | — | — | EP | disclosed |
| EP-2928890-B1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARM SPA (IT) | 2018-02-28 | — | — | EP | disclosed |
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| US-20180037557-A1 | PRODRUGS RILUZOLE AND THEIR METHOD OF USE | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2018-02-08 | — | — | US | disclosed |
| WO-2018027021-A1 | SYNTHESIS OF (S)-2-AMINO-4-METHYL-1-((R)-2-METHYLOXIRANE-2-YL)-PENTAN-1-ONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | AMGEN INC. (US) | 2018-02-08 | — | — | WO | disclosed |
| US-20180022699-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA L.P. | 2018-01-25 | — | — | US | disclosed |
| CN-105636945-B | Optionally substituted quinoline compounds | 卫材R&D管理有限公司 | 2017-11-17 | — | — | CN | disclosed |
| US-20170283377-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-10-05 | — | — | US | disclosed |
| US-20170260145-A1 | HETEROCYCLIC KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170250079-A1 | RESIST UNDERLAYER FILM-FORMING COMPOSITION | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-08-31 | — | — | US | disclosed |
| US-20170250079-A1 | RESIST UNDERLAYER FILM-FORMING COMPOSITION | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-08-31 | — | — | US | disclosed |
| CN-107108552-A | Heterocyclic kinase inhibitors | 百时美施贵宝公司 | 2017-08-29 | — | — | CN | disclosed |
| US-20170239249-A1 | QUINAZOLINE-BASED KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-24 | — | — | US | disclosed |
| US-9737542-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9708337-B2 | Aryl amide-based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| CN-104470523-B | Compound based on imidazo [1,2 b] pyridazine, comprising their compositions and its application method | 莱西肯医药有限公司 | 2017-07-11 | — | — | CN | disclosed |
| US-9682933-B2 | Androgen receptor modulators and methods for their use | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2017-06-20 | — | — | US | disclosed |
| US-9663486-B2 | Selectively substituted quinoline compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| US-20170144969-A1 | ANTIMICROBIAL CONJUGATES, METHOD FOR PRODUCTION AND USES THEREOF | THE SECRETARY OF STATE FOR HEALTH (GB) | 2017-05-25 | — | — | US | disclosed |
| US-20170144969-A1 | ANTIMICROBIAL CONJUGATES, METHOD FOR PRODUCTION AND USES THEREOF | THE SECRETARY OF STATE FOR HEALTH (GB) | 2017-05-25 | — | — | US | disclosed |
| US-20170107203-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | EPIRUS BIOPHARMACEUTICALS, INC. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170107203-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | EPIRUS BIOPHARMACEUTICALS, INC. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170107203-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | EPIRUS BIOPHARMACEUTICALS, INC. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170096454-A1 | CYCLOHEPTAPEPTIDE AGENTS FOR TREATMENT OF CANCER AND OBESITY DISEASES | HONG KONG BAPTIST UNIVERSITY (HK) | 2017-04-06 | — | — | US | disclosed |
| US-20170057911-A1 | SYNTHESIS OF ARYL CYCLOHEXANE CARBOXAMIDE DERIVATIVES USEFUL AS SENSATES IN CONSUMER PRODUCTS | PROCTER & GAMBLE (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170057964-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2017-03-02 | — | — | US | disclosed |
| EP-3110799-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | Epirus Biopharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2958924-B1 | 5H-CHROMENO[3,4-C]PYRIDINES AS INHIBITORS OF ADAPTOR ASSOCIATED KINASE 1 (AAK1) | BRISTOL MYERS SQUIBB CO (US) | 2016-12-28 | — | — | EP | disclosed |
| WO-2016185450-A1 | AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2016-11-24 | — | — | WO | disclosed |
| US-20160326111-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA LP (US) | 2016-11-10 | — | — | US | disclosed |
| US-9487479-B2 | Small molecule inhibitors of N-terminus activation of the androgen receptor | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-11-08 | — | — | US | disclosed |
| US-9487479-B2 | Small molecule inhibitors of N-terminus activation of the androgen receptor | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2016-11-08 | — | — | US | disclosed |
| CN-105979950-A | Pyrrolotriazine kinase inhibitors | 百时美施贵宝公司 | 2016-09-28 | — | — | CN | disclosed |
| US-9453013-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-09-27 | — | — | US | disclosed |
| US-9453013-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-09-27 | — | — | US | disclosed |
| US-9434760-B2 | Prolinamide derivatives as thrombin inhibitors, preparation method and application thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2016-09-06 | — | — | US | disclosed |
| US-20160243125-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-25 | — | — | US | disclosed |
| EP-3057948-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2016-08-24 | — | — | EP | disclosed |
| EP-2331501-B1 | SMALL MOLECULE INHIBITORS OF N-TERMINUS ACTIVATION OF THE ANDROGEN RECEPTOR | BRITISH COLUMBIA CANCER AGENCY (CA) | 2016-07-20 | — | — | EP | disclosed |
| US-20160176841-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-06-23 | — | — | US | disclosed |
| US-20160152621-A1 | ARYL LACTAM KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| CN-105636945-A | Optionally substituted quinoline compounds | EISAI R&D MAN CO LTD | 2016-06-01 | — | — | CN | disclosed |
| EP-3019475-A1 | ARYL AMIDE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-05-18 | — | — | EP | disclosed |
| US-20160108049-A1 | Novel Phthalazinone-Pyrrolopyrimidinecarboxamide Derivatives | ASTRAZENECA AB (SE) | 2016-04-21 | — | — | US | disclosed |
| CN-105517993-A | Aryl amide kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2016-04-20 | — | — | CN | disclosed |
| US-20160024093-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160016967-A1 | ARYL AMIDE-BASED KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
| US-20160016939-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | NATIONAL CENTER FOR ADDICTION STUDIES AND TREATMENT FOUNDATION | 2016-01-21 | — | — | US | disclosed |
| US-20160016939-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | NATIONAL CENTER FOR ADDICTION STUDIES AND TREATMENT FOUNDATION | 2016-01-21 | — | — | US | disclosed |
| EP-2961403-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | Zalicus Pharmaceuticals Ltd. (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-2721030-B1 | NOVEL PHTHALAZINONE-PYRROLOPYRIMIDINECARBOXAMIDE DERIVATIVES | TAKEDA GMBH (DE) | 2015-12-16 | — | — | EP | disclosed |
| US-9212139-B2 | Aryl substituted indoles and their use as blockers of sodium channels | PURDUE PHARMA, L.P. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150344424-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2015-12-03 | — | — | US | disclosed |
| CN-105121445-A | 5H-chromeno[3,4-c]pyridines as inhibitors of adaptor associated kinase 1 (AAK1) | BRISTOL MYERS SQUIBB CO | 2015-12-02 | — | — | CN | disclosed |
| EP-2318361-B1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| EP-2318361-B1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| WO-2015127549-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | PAJOUHESH HASSAN (CA) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015127549-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | PAJOUHESH HASSAN (CA) | 2015-09-03 | — | — | WO | disclosed |
| CN-102656179-B | Bufalin derivatives, pharmaceutical compositions and uses thereof | SUZHOU NEUPHARMA Co.,Ltd. (CN) | 2015-07-29 | — | — | CN | disclosed |
| US-9062028-B2 | Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150139916-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-05-21 | — | — | US | disclosed |
| US-9018197-B2 | Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use | SUZHOU NEUPHARMA CO. LTD. (CN) | 2015-04-28 | — | — | US | disclosed |
| WO-2015057655-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | disclosed |
| EP-2440558-B1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL (JP) | 2015-04-01 | — | — | EP | disclosed |
| US-8980913-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-03-17 | — | — | US | disclosed |
| US-8980913-B2 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-03-17 | — | — | US | disclosed |
| US-8969565-B2 | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| WO-2015006100-A1 | ARYL AMIDE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-15 | — | — | WO | disclosed |
| EP-2824097-A1 | Prolinamide derivative as thrombin inhibitor, preparation method and application thereof | Shanghai Institute of Pharmaceutical Industry (CN) | 2015-01-14 | — | — | EP | disclosed |
| EP-2822559-A1 | IMIDAZO [1, 2 - B]PYRIDAZINE - BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF | Lexicon Pharmaceuticals, Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| CN-102459267-B | Dihydropyrrolonaphtyridinone compounds as inhibitors of JAK | TAKEDA PHARMACEUTICAL | 2014-11-26 | — | — | CN | disclosed |
| US-8895497-B2 | Cathepsin S inhibitors | DCB-USA, LLC (US) | 2014-11-25 | — | — | US | disclosed |
| US-8841291-B2 | Selective hydroxamic acid based MMP-12 and MMP-13 inhibitors | NOVARTIS AG (CH) | 2014-09-23 | — | — | US | disclosed |
| US-8841291-B2 | Selective hydroxamic acid based MMP-12 and MMP-13 inhibitors | NOVARTIS AG (CH) | 2014-09-23 | — | — | US | disclosed |
| WO-2014134306-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | Zalicus Pharmaceuticals, Ltd. (US) | 2014-09-04 | — | — | WO | disclosed |
| WO-2014134306-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | Zalicus Pharmaceuticals, Ltd. (US) | 2014-09-04 | — | — | WO | disclosed |
| US-8785429-B2 | Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2014-07-22 | — | — | US | disclosed |
| US-20140163066-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-06-12 | — | — | US | disclosed |
| WO-2014086927-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-06-12 | — | — | WO | disclosed |
| US-20140163066-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2014-06-12 | — | — | US | disclosed |
| US-20140112945-A1 | NOVEL PHTHALAZINONE-PYRROLOPYRIMIDINECARBOXAMIDE DERIVATIVES | TAKEDA GMBH (DE) | 2014-04-24 | — | — | US | disclosed |
| EP-2721030-A1 | NOVEL PHTHALAZINONE-PYRROLOPYRIMIDINECARBOXAMIDE DERIVATIVES | Takeda GmbH (DE) | 2014-04-23 | — | — | EP | disclosed |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-03-20 | — | — | US | disclosed |
| US-20140031399-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2014-01-30 | — | — | US | disclosed |
| US-20140031399-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2014-01-30 | — | — | US | disclosed |
| US-20130296245-A1 | PROLINAMIADE DERIVATIVES AS THROMBIN INHIBITOR, PREPRARATION METHOD AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2013-11-07 | — | — | US | disclosed |
| US-20130296281-A1 | Aryl Substituted Indoles and Their Use as Blockers of Sodium Channels | PURDUE PHARMA L.P. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130245021-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2013-09-19 | — | — | US | disclosed |
| EP-2639230-A1 | PROLINAMIDE DERIVATIVE AS THROMBIN INHIBITOR, PREPARATION METHOD AND APPLICATION THEREOF | Shanghai Institute of Pharmaceutical Industry (CN) | 2013-09-18 | — | — | EP | disclosed |
| WO-2013134219-A1 | IMIDAZO [1, 2 - B] PYRIDAZINE - BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF | LEXICON PHARMACEUTICALS, INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| US-8501772-B2 | 3,8-diaminotetrahydroquinoline derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8501772-B2 | 3,8-diaminotetrahydroquinoline derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20130190324-A1 | TOPICAL OCULAR DRUG DELIVERY | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130184252-A1 | DIHYDROPYRROLONAPHTHYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-18 | — | — | US | disclosed |
| US-8420816-B2 | Dihydropyrrolonaphthyridinone compounds as inhibitors of JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-16 | — | — | US | disclosed |
| US-20130012537-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-10 | — | — | US | disclosed |
| WO-2012171900-A1 | NOVEL PHTHALAZINONE-PYRROLOPYRIMIDINECARBOXAMIDE DERIVATIVES | NYCOMED GMBH (DE) | 2012-12-20 | — | — | WO | disclosed |
| US-8299255-B2 | 3,8-diaminotetrahydroquinoline derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| CN-102464701-A | Novel compound, preparation method and application thereof | SHANGHAI INST PHARM INDUSTRY | 2012-05-23 | — | — | CN | disclosed |
| CN-102459267-A | Dihydropyrrolonaphtyridinone compounds as inhibitors of jak | TAKEDA PHARMACEUTICAL | 2012-05-16 | — | — | CN | disclosed |
| WO-2012027957-A1 | BUFALIN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | SUZHOU NEUPHARMA CO., LTD. (CN) | 2012-03-08 | — | — | WO | disclosed |
| US-8129417-B2 | Substituted octahydrocyclopenta[C]pyrrol-4-amines as calcium channel blockers | ABBOTT LABORATORIES (US) | 2012-03-06 | — | — | US | disclosed |
| US-20120053162-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | SUZHOU NEUPHARMA CO. LTD. (CN) | 2012-03-01 | — | — | US | disclosed |
| CN-102292319-A | Novel substituted octahydrocyclopenta(C)pyrrol-4-amines as calcium channel blockers | — | 2011-12-21 | — | — | CN | disclosed |
| WO-2011149995-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA [C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
| EP-2367790-A2 | SUBSTITUTED OCTAHYDROCYCLOPENTA(C)PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110230539-A1 | Small Molecule Inhibitors of N-Terminus Activation of the Androgen Receptor | THE UNITED STATES GOVERNMENT | 2011-09-22 | — | — | US | disclosed |
| US-20110230539-A1 | Small Molecule Inhibitors of N-Terminus Activation of the Androgen Receptor | THE UNITED STATES GOVERNMENT | 2011-09-22 | — | — | US | disclosed |
| US-20110136780-A1 | DIHYDROPYRROLONAPHTYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-09 | — | — | US | disclosed |
| WO-2011069149-A2 | CATHEPSIN S INHIBITORS | DCB-USA LLC (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20110112076-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2011-05-12 | — | — | US | disclosed |
| US-20110112076-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2011-05-12 | — | — | US | disclosed |
| EP-2318361-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | Novartis AG (CH) | 2011-05-11 | — | — | EP | disclosed |
| US-20100317693-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | ZERIA PHARMACEUTICAL CO., LTD (JP) | 2010-12-16 | — | — | US | disclosed |
| EP-2241564-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | Zeria Pharmaceutical Co., Ltd. (JP) | 2010-10-20 | — | — | EP | disclosed |
| WO-2010062927-A2 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA(C)PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-05-27 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
| US-7651997-B2 | Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2010-01-26 | — | — | US | disclosed |
| WO-2010007027-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007027-A1 | SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| US-20100004250-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-07 | — | — | US | disclosed |
| US-20090306053-A1 | Highly selective rho-kinase inhibitor | D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-1625153-B1 | ACYLATED LYSOBACTIN-TYPE NONADEPSIPEPTIDES | AICURIS GMBH & CO KG (DE) | 2009-08-26 | — | — | EP | disclosed |
| US-7579346-B2 | (R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]4-methylvaleramide, for example; inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors | MERCK PATENT GMBH (DE) | 2009-08-25 | — | — | US | disclosed |
| US-7579346-B2 | (R)-2-[(5-chlorothiophene-2-carbonyl)amino]-N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]4-methylvaleramide, for example; inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors | MERCK PATENT GMBH (DE) | 2009-08-25 | — | — | US | disclosed |
| WO-2009098901-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-13 | — | — | WO | disclosed |
| EP-0976722-B1 | BENZAMIDINE DERIVATIVES | AJINOMOTO KK (JP) | 2009-03-11 | — | — | EP | disclosed |
| EP-1878732-B1 | HIGHLY SELECTIVE Rho-KINASE INHIBITOR | WESTERN THERAPEUTICS INST INC (JP) | 2009-02-25 | — | — | EP | disclosed |
| US-7396844-B1 | Benzamidine derivatives | AJINOMOTO CO., INC. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-7368424-B2 | Acylated nonadepsipeptides | AICURIS GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
| EP-1878732-A1 | HIGHLY SELECTIVE Rho-KINASE INHIBITOR | D. Western Therapeutics Institute (JP) | 2008-01-16 | — | — | EP | disclosed |
| US-7285552-B2 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| EP-1338588-B1 | METHOD OF RESOLVING OPTICAL ISOMERS OF AMINO ACID DERIVATIVE | TOKUYAMA CORP (JP) | 2007-09-26 | — | — | EP | disclosed |
| US-7265220-B2 | Amino acid derivatives, method for production thereof and pharmaceutical compositions comprising said derivative | LES LABORATORIES SERVIER (FR) | 2007-09-04 | — | — | US | disclosed |
| EP-1809657-A1 | CYCLIC NONAPEPTIDE AMIDES | AiCuris GmbH & Co. KG (DE) | 2007-07-25 | — | — | EP | disclosed |
| US-7199264-B2 | Method of resolving optical isomers of amino acid derivative | TOKUYAMA CORPORATION (JP) | 2007-04-03 | — | — | US | disclosed |
| US-7119091-B2 | Triazaspiro[5.5]undecane derivatives and pharmaceutical compositions comprising thereof, as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-10-10 | — | — | US | disclosed |
| WO-2006048156-A1 | CYCLIC NONAPEPTIDE AMIDES | AICURIS GMBH & CO. KG (DE) | 2006-05-11 | — | — | WO | disclosed |
| US-7037939-B2 | Compound and derivative of gabapentin | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUE (TW) | 2006-05-02 | — | — | US | disclosed |
| CN-1246321-C | Triazaspiro [5,5] undecane derivatives and pharmaceutical compositions containing the same as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2006-03-22 | — | — | CN | disclosed |
| EP-1625153-A1 | ACYLATED LYSOBACTIN-TYPE NONADEPSIPEPTIDES | Bayer HealthCare AG (DE) | 2006-02-15 | — | — | EP | disclosed |
| US-20050085517-A1 | Novel amino acid derivatives, method for production thereof and pharmaceutical compositions comprising said derivative | LES LABORATOIRES SERVIER (FR) | 2005-04-21 | — | — | US | disclosed |
| US-20050075281-A1 | peptide antibiotics comprising lysobactin derivatives used for treatment and/or prophylaxis of bacterial infectious diseases; cyclic peptides | BAYER HEALTHCARE AG (DE) | 2005-04-07 | — | — | US | disclosed |
| US-20040248811-A1 | Compound and derivative of gabapentin | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2004-12-09 | — | — | US | disclosed |
| EP-1236726-B1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2004-12-01 | — | — | EP | disclosed |
| WO-2004099239-A1 | ACYLATED LYSOBACTIN-TYPE NONADEPSIPEPTIDES | BAYER HEALTHCARE AG (DE) | 2004-11-18 | — | — | WO | disclosed |
| EP-1476421-A2 | NOVEL AMINO ACID DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID DERIVATIVE | LES LABORATOIRES SERVIER (FR) | 2004-11-17 | — | — | EP | disclosed |
| CN-1533390-A | Pharmaceutical composition comprising triazaspiro [5.5] undecane derivative as active ingredient | СҰҩƷ��ҵ��ʽ���� | 2004-09-29 | — | — | CN | disclosed |
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
| US-20040106619-A1 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | ONO PHARMACEUTICALS CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| WO-2004046138-A1 | CARBOXAMIDES | MERCK PATENT GMBH (DE) | 2004-06-03 | — | — | WO | disclosed |
| US-20040102646-A1 | Method of resolving optical isomers of amino acid derivative | TOKUYAMA CORPORATION (JP) | 2004-05-27 | — | — | US | disclosed |
| US-20040097511-A1 | Triazaspiro[5.5]undecane derivatives and drugs containing the same as the active ingredient | PANASONIC CORPORATION (JP) | 2004-05-20 | — | — | US | disclosed |
| WO-2004022534-A1 | ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS | NPS ALLELIX CORP. (CA) | 2004-03-18 | — | — | WO | disclosed |
| CN-1473145-A | Method for separating optical isomers of amino acid derivatives | ��ʽ�����ɽ | 2004-02-04 | — | — | CN | disclosed |
| EP-1378509-A1 | DRUGS CONTAINING TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-01-07 | — | — | EP | disclosed |
| CN-1130347-C | Novel 2,3-methylene amino acid compound, prepn. method therefor, pharmaceutical compositions contg. same | SOVIL LAB (FR) | 2003-12-10 | — | — | CN | disclosed |
| WO-2003070690-A2 | NOVEL AMINO ACID DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID DERIVATIVE | LES LABORATOIRES SERVIER (FR) | 2003-08-28 | — | — | WO | disclosed |
| EP-1338588-A1 | METHOD OF RESOLVING OPTICAL ISOMERS OF AMINO ACID DERIVATIVE | TOKUYAMA CORPORATION (JP) | 2003-08-27 | — | — | EP | disclosed |
| CN-1433419-A | Triazaspiro [5,5] undecane derivatives and pharmaceutical compositions containing the same as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2003-07-30 | — | — | CN | disclosed |
| EP-1236726-A1 | TRIAZASPIRO 5.5]UNDECANE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-09-04 | — | — | EP | disclosed |
| US-6399629-B1 | PYRROLIDINES AND PIPERIDINES FOR TREATING MICROBIAL INFECTIONS BY REDUCING EXPORT OF COADMINISTERED ANTIMICROBIAL AGENT OR COMPOUND SYNTHESIZED BY MICROBES FOR THEIR GROWTH; REDUCING IN VIVO AVAILABILITY | MICROCIDE PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | disclosed |
| EP-1050534-B1 | 2,3-methano-amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2001-12-05 | — | — | EP | disclosed |
| US-6288077-B1 | 2-AZABICYCLO(3.1.0)HEXANE-1,2-DICARBOXYLIC AMIDE OR 2-AZABICYCLO(4.1.0)HEPTANE-1,2-DICARBOXYLIC AMIDE DERIVATIVE; TRYPSIN-LIKE SERINE PROTEASE INHIBITOR; ANTICOAGULANTS | ADIR ET COMPAGNIE (FR) | 2001-09-11 | — | — | US | disclosed |
| CN-1277961-A | Novel 2,3-methylene amino acid compound, prepn. method therefor, pharmaceutical compositions contg. same | ADIR (FR) | 2000-12-27 | — | — | CN | disclosed |
| EP-1050534-A1 | 2,3-methano-amino acid derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 2000-11-08 | — | — | EP | disclosed |
| EP-0976722-A1 | BENZAMIDINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2000-02-02 | — | — | EP | disclosed |
| CN-1243505-A | Benzamidine derivatives | AJINOMOTO KK (JP) | 2000-02-02 | — | — | CN | disclosed |
| WO-2000001714-A1 | EFFLUX PUMP INHIBITORS | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| EP-0717040-A1 | Thiazine or thiazepine derivatives which inhibit NOS | Japan Tobacco Inc. (JP) | 1996-06-19 | — | — | EP | disclosed |
| CN-1124734-A | Thiazine- or thiazepine-derivatives | JAPAN TOBACCO INC (JP) | 1996-06-19 | — | — | CN | disclosed |
| US-5494898-A | DIQUATERNARY TRIPEPTIDES | OHMEDA PHARMACEUTICAL PRODUCTS DIVISION INC. (US) | 1996-02-27 | — | — | US | disclosed |
| US-5298409-A | Of esters, antigen diastereomers which are stable analogs of the unstable ester transition states | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-03-29 | — | — | US | disclosed |
| US-5190865-A | Antibody-enhanced stereospecific hydrolyses | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1993-03-02 | — | — | US | disclosed |
| EP-0498941-A2 | Peptide skeletal muscle relaxants | BOC Health Care, Inc. (US) | 1992-08-19 | — | — | EP | disclosed |
| EP-0189803-B1 | INDOL-3-YL-QUINAZOLINO-1,4-BENZODIAZEPIN-5,13-DIONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK & CO. INC. (US) | 1990-04-25 | — | — | EP | disclosed |
| EP-0295316-A2 | Antitumor amino acid and peptide derivatives of 1,4-bis[ (aminoalkyl and hydroxyaminoalkyl)- amino]-5,8 dihydroxyanthraquinones | AMERICAN CYANAMID COMPANY (US) | 1988-12-21 | — | — | EP | disclosed |
| US-4732970-A | Antitumor amino acid and peptide derivatives of 1,4-bis(aminoalkyl and hydroxy-aminoalkyl)amino)-5,8-dihydroxyanthraquinones | AMERICAN CYANAMID COMPANY (US) | 1988-03-22 | — | — | US | disclosed |
| EP-0189803-A1 | Indol-3-yl-quinazolino-1,4-benzodiazepin-5,13-diones, process for their preparation and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1986-08-06 | — | — | EP | disclosed |
| US-4559339-A | CENTRAL NERVOUS SYSTEM, GASTROINTESTINAL DISORDERS | MERCK & CO., INC. (US) | 1985-12-17 | — | — | US | disclosed |
| US-4507232-A | Peptide derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1985-03-26 | — | — | US | disclosed |
| EP-0113996-A2 | Peptide derivatives | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1984-07-25 | — | — | EP | disclosed |
| US-4228157-A | Synthetic peptides having pituitary growth hormone releasing activity | BECKMAN INSTRUMENTS, INC. (US) | 1980-10-14 | — | — | US | disclosed |
| US-3971736-A | HEXA- AND HEPTA-PEPTIDES, ANTIINFLAMMATORY, ANTIULCER, ANTIARTHRITIC | MERCK & CO., INC. (US) | 1976-07-27 | — | — | US | disclosed |
| US-3971736-A | HEXA- AND HEPTA-PEPTIDES, ANTIINFLAMMATORY, ANTIULCER, ANTIARTHRITIC | MERCK & CO., INC. (US) | 1976-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163066-A1 | COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | ADRB2, ADRB1, ADRA2B | CTSL 2974/4885CTSS 2939/4885CTSK 3003/4885 |
| US-20160152621-A1 | ARYL LACTAM KINASE INHIBITORS | AAK1, ADCK1, ANKK1 | CTSL 3992/4885CTSS 3931/4885CTSK 1026/4885 |
| US-11845737-B2 | Process for preparing a Cot inhibitor compound | TPO, TFPI, TFPI2 | CTSL 2655/4885CTSS 2588/4885CTSK 1838/4885 |
| US-20230381150-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | CTSL 12/4885CTSS 653/4885CTSK 586/4885 |
| US-20200131173-A1 | VMAT2 INHIBITOR COMPOUNDS AND COMPOSITIONS THEREOF | SLC18A2, SLC6A2, SLC18A3 | CTSL 3998/4885CTSS 2297/4885CTSK 2685/4885 |
| US-20130296245-A1 | PROLINAMIADE DERIVATIVES AS THROMBIN INHIBITOR, PREPRARATION METHOD AND APPLICATION THEREOF | PREP, TFPI, PEPD | CTSL 66/4885CTSS 280/4885CTSK 265/4885 |
| US-10905681-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CTSL 12/4885CTSS 653/4885CTSK 586/4885 |
| US-20160176841-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | SSB, TLR7, TLR8 | CTSL 1162/4885CTSS 1423/4885CTSK 1037/4885 |
| US-12122765-B2 | Methods and intermediates for preparing therapeutic compounds | CYP11A1, CYP11B1, CYP11B2 | CTSL 216/4885CTSS 728/4885CTSK 1742/4885 |
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | CETP, LIPA, MTTP | CTSL 1366/4885CTSS 2330/4885CTSK 2251/4885 |
| US-20200289475-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | CTSL 12/4885CTSS 653/4885CTSK 586/4885 |
| US-20210395299-A1 | NOVEL DIPEPTIDE COMPOUNDS AND USES THEREOF | PEPD, SERPINC1, VIP | CTSL 174/4885CTSS 745/4885CTSK 418/4885 |
| US-20040102646-A1 | Method of resolving optical isomers of amino acid derivative | ALAD, AAAS, BCAT1 | CTSL 1559/4885CTSS 4304/4885CTSK 4361/4885 |
| US-20220380340-A1 | PROCESS FOR PREPARING A COT INHIBITOR COMPOUND | TPO, TFPI, TFPI2 | CTSL 2655/4885CTSS 2588/4885CTSK 1838/4885 |
| US-20040106619-A1 | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient | NONO, NAA15, USO1 | CTSL 2757/4885CTSS 3155/4885CTSK 3918/4885 |
| US-20180036290-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | CTSL 12/4885CTSS 653/4885CTSK 586/4885 |
| US-20090306053-A1 | Highly selective rho-kinase inhibitor | ROCK1, ROCK2, RHOT2 | CTSL 4319/4885CTSS 3303/4885CTSK 2990/4885 |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | CTSL 145/4885CTSS 1265/4885CTSK 1499/4885 |
| US-20220213111-A1 | SUBSTITUTED HETEROCYCLES AS CYCLIC TREX1 INHIBITORS | TMX1, TREH, TSNAX | CTSL 3028/4885CTSS 2838/4885CTSK 3200/4885 |
| US-20160016967-A1 | ARYL AMIDE-BASED KINASE INHIBITORS | AAK1, ADCK1, NCK1 | CTSL 4532/4885CTSS 4233/4885CTSK 1377/4885 |
| US-20190085026-A1 | AN IMPROVED PROCESSES FOR THE PREPARATION OF CARFILZOMIB OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | PRCP, SF3B5, GBA1 | CTSL 64/4885CTSS 139/4885CTSK 201/4885 |
| US-11932628-B2 | Selective small molecule peptidomimetic melanocortin ligands | MC1R, MC3R, MC4R | CTSL 3505/4885CTSS 3135/4885CTSK 2752/4885 |
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | SLC1A2, SLC6A7, SLC1A1 | CTSL 2736/4885CTSS 1973/4885CTSK 2451/4885 |
| US-10364269-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | SF3B5, PRCP, GBA1 | CTSL 81/4885CTSS 132/4885CTSK 252/4885 |
| US-20050075281-A1 | peptide antibiotics comprising lysobactin derivatives used for treatment and/or prophylaxis of bacterial infectious diseases; cyclic peptides | VIP, LNPEP, HAMP | CTSL 65/4885CTSS 459/4885CTSK 393/4885 |
| US-20170144969-A1 | ANTIMICROBIAL CONJUGATES, METHOD FOR PRODUCTION AND USES THEREOF | SRM, SMS, SMOX | CTSL 601/4885CTSS 719/4885CTSK 1412/4885 |
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | CTSL 1186/4885CTSS 1732/4885CTSK 2107/4885 |
| US-10253027-B2 | Aryl lactam kinase inhibitors | AAK1, ADCK1, ANKK1 | CTSL 3992/4885CTSS 3931/4885CTSK 1026/4885 |
| US-12005046-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CTSL 12/4885CTSS 653/4885CTSK 586/4885 |
| US-20130012537-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | MC2R, GHRHR, REN | CTSL 2793/4885CTSS 3940/4885CTSK 4355/4885 |
| US-20130184252-A1 | DIHYDROPYRROLONAPHTHYRIDINONE COMPOUNDS AS INHIBITORS OF JAK | JAK2, JAK1, JAK3 | CTSL 2201/4885CTSS 3087/4885CTSK 2726/4885 |
| US-20200390760-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | CTSL 2296/4885CTSS 3381/4885CTSK 1442/4885 |
| US-20250269043-A1 | TARGETED BIFUNCTIONAL DEGRADERS | SMURF2, SMURF1, MDM2 | CTSL 577/4885CTSS 346/4885CTSK 534/4885 |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CTSL 3165/4885CTSS 2960/4885CTSK 2874/4885 |
| US-20170283377-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, UTS2R, MC2R | CTSL 4372/4885CTSS 3968/4885CTSK 4541/4885 |
| US-20220388947-A1 | Nitrogen-containing Derivative of Substituted Phenol Hydroxy Acid Ester, and Preparation and Use Thereof | EGLN2, EGLN3, HPD | CTSL 3363/4885CTSS 3527/4885CTSK 4269/4885 |
| US-11583538-B2 | Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors | TMX1, P2RX1, TCOF1 | CTSL 3478/4885CTSS 3702/4885CTSK 4170/4885 |
| US-20220111056-A1 | DRUG-LOADED EMULSION | SLC43A1, SLC7A1, CETP | CTSL 1794/4885CTSS 3871/4885CTSK 4165/4885 |
| US-20110230539-A1 | Small Molecule Inhibitors of N-Terminus Activation of the Androgen Receptor | AR, KLK3, NR5A1 | CTSL 2310/4885CTSS 1778/4885CTSK 2207/4885 |
| US-20040248811-A1 | Compound and derivative of gabapentin | GABRA4, NPY4R, CNR2 | CTSL 4427/4885CTSS 4162/4885CTSK 4212/4885 |
| US-10800809-B2 | Processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof | SF3B5, PRCP, GBA1 | CTSL 81/4885CTSS 132/4885CTSK 252/4885 |
| US-11911369-B2 | Prodrugs of riluzole and their method of use | APEH, UGT1A9, ALDH3A1 | CTSL 6/4885CTSS 503/4885CTSK 543/4885 |
| US-20130296281-A1 | Aryl Substituted Indoles and Their Use as Blockers of Sodium Channels | SCN5A, TRPV1, TRPV5 | CTSL 3744/4885CTSS 2773/4885CTSK 3507/4885 |
| US-11040970-B2 | VMAT2 inhibitor compounds and compositions thereof | SLC18A2, SLC6A2, SLC18A3 | CTSL 3998/4885CTSS 2297/4885CTSK 2685/4885 |
| US-10208023-B2 | Heterocyclic inhibitors of the sodium channel | SCN1B, TRPV1, SCN1A | CTSL 3400/4885CTSS 1444/4885CTSK 3043/4885 |
| US-20120053162-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | UGT2B7, BCCIP, ABCG2 | CTSL 3064/4885CTSS 1720/4885CTSK 2865/4885 |
| US-20160326111-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | TRPC5, TRPV5, TRPV1 | CTSL 3565/4885CTSS 2491/4885CTSK 3321/4885 |
| US-20250281424-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | PF4, F12, F2 | CTSL 3865/4885CTSS 3675/4885CTSK 3949/4885 |
| US-20160016939-A1 | HETEROCYCLIC INHIBITORS OF THE SODIUM CHANNEL | SCN1B, TRPV1, SCN1A | CTSL 3400/4885CTSS 1444/4885CTSK 3043/4885 |
| US-20160024093-A1 | IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | IRAK2, IRAK1, GRB2 | CTSL 4683/4885CTSS 4728/4885CTSK 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.